Technology
Health
Biotechnology
CytomX
$10.519876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$10.51
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.24 (-2.23%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell CytomX and other stocks, options, ETFs, and crypto commission-free!
About
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Read More The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Employees
137
Headquarters
South San Francisco, California
Founded
2010
Market Cap
484.64M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
446.20K
High Today
$10.93
Low Today
$10.21
Open Price
$10.50
Volume
264.82K
52 Week High
$32.55
52 Week Low
$9.38
Collections
Technology
Health
Biotechnology
Therapy
Cancer Prevention
2015 IPO
US
North America
News
Yahoo Finance14h
The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM) (NASDAQ: AXSM) Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (NASDAQ: CPRX) CYCLERION THERA/SH (NASDAQ: CYCNV) (NASDAQ: CYCNV) Veracyte Inc (NASDAQ: VCYT) Down In The Dumps (Biotech stocks hitting 52-week lows on March 25) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (NASDAQ: ADMS) Assembly Biosciences Inc (NASDAQ: ...
Seeking AlphaMar 25
CytomX finance chief bids adieu
CytomX Therapeutics (NASDAQ:CTMX) announces that CFO Debanjan Ray will resign on May 15 to accept the CEO job at an unnamed biotech startup.
Seeking AlphaFeb 27
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2018 Results - Earnings Call Transcript
CytomX Therapeutics (NASDAQ:CTMX) Q4 2018 Earnings Conference Call February 27, 2019 5:00 PM ET Company Participants Chris Keenan - VP, IR Sean McCarthy - President, CEO & Chairman Debanjan Ray - CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Boris Peaker - Cowen Robert Burns - H.C. Wainwright Mohit Bansal - Citi Jackson Harvey - Nomura Joe Catanzaro - Piper Jaffray Peter Lawson - SunTrust Robinson Operator Good afternoon, and welcome to the CytomX 2018 Full-Ye...
Price Paid on Robinhood
16% Lower
Right Now
52 Week Low
$9.38
Average Price Paid
$12.57
52 Week High
$32.55
Earnings
-$0.74
-$0.33
$0.08
$0.49
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, After Hours